tiprankstipranks
Surrozen presents preliminary results from Phase 1a study of SZN-043
PremiumThe FlySurrozen presents preliminary results from Phase 1a study of SZN-043
5M ago
Surrozen initiates dosing of first patient in Phase 1b trial of SZN-043
Premium
The Fly
Surrozen initiates dosing of first patient in Phase 1b trial of SZN-043
6M ago
Surrozen presents data demonstrating potentialfor Wnt mimetic technologies
Premium
The Fly
Surrozen presents data demonstrating potentialfor Wnt mimetic technologies
7M ago
Surrozen publishes study in ‘Respiratory Research’ on Wnt mimetic tech potential
PremiumThe FlySurrozen publishes study in ‘Respiratory Research’ on Wnt mimetic tech potential
8M ago
Surrozen Highlights SZN-043 Data on Safety and Liver Function
Premium
Company Announcements
Surrozen Highlights SZN-043 Data on Safety and Liver Function
8M ago
Surrozen announces up to $192.5M private placement
Premium
The Fly
Surrozen announces up to $192.5M private placement
8M ago
Surrozen prioritizes development of SZN-043 for alcohol-associated hepatitis
PremiumThe FlySurrozen prioritizes development of SZN-043 for alcohol-associated hepatitis
10M ago
Surrozen to discontinue clinical development of SZN-1326 in IBD
Premium
The Fly
Surrozen to discontinue clinical development of SZN-1326 in IBD
10M ago
Surrozen Inc trading halted, news pending
Premium
The Fly
Surrozen Inc trading halted, news pending
11M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100